# OnCo record her2-positive-early-breast-cancer (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/her2-positive-early-breast-cancer/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "her2-positive-early-breast-cancer" ;
  schema:name "Early HER2-positive breast cancer"@en ;
  schema:alternateName "Stage I to III HER2-positive breast cancer"@en, "Operable HER2-positive breast cancer"@en, "HER2-positive breast cancer treated with curative intent"@en ;
  schema:description "HER2-positive breast cancer caught early is usually cured. Chemotherapy with the antibodies trastuzumab and pertuzumab comes before surgery; if the tumour has gone by then, antibodies alone finish the year, and if cancer remains, trastuzumab emtansine or trastuzumab deruxtecan take over. Small tumours get a gentler regimen, and trials now ask how much treatment can be left out."@en ;
  schema:url <https://onco.cc/cancers/her2-positive-early-breast-cancer/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/HER2-positive_breast_cancer> ;
  schema:citation <https://doi.org/10.1056/NEJMoa1814017>, <https://doi.org/10.1056/NEJMoa1703643>, <https://doi.org/10.1016/S1470-2045(18)30570-9>, <https://en.wikipedia.org/wiki/HER2-positive_breast_cancer> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/trials/destiny-breast05/>, <https://onco.cc/trials/destiny-breast11/>, <https://onco.cc/trials/phergain/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/technologies/her2-pet/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/trastuzumab-rezetecan/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:standardOfCare <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/trials/apt-trial/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/trials/train-2/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/trials/destiny-breast11/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/trials/aphinity/>, <https://onco.cc/trials/hera-b31-n9831/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/trials/destiny-breast05/>, <https://onco.cc/drugs/trastuzumab-emtansine/>, <https://onco.cc/trials/katherine/>, <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/lumpectomy/>, <https://onco.cc/terms/mastectomy/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/technologies/hypofractionated-radiotherapy/>, <https://onco.cc/terms/trastuzumab-cardiotoxicity/> .